3 Biotechs With Major Catalysts Incoming

FDA advisory committees might determine the future for Exact Sciences, Durata Therapeutics, and MannKind Corporation beginning at the end of March.

Mar 19, 2014 at 9:43AM

The end of March will be a nerve racking stretch for these three companies. Each one has nearly everything riding on a single product. Top management from Exact Sciences Corporation (NASDAQ:EXAS)Durata Therapeutics (NASDAQ:DRTX), and MannKind Corporation (NASDAQ:MNKD) are all facing perhaps the most important moments of their careers, beginning March 27.

Before making an approval decision, the FDA often assembles an advisory committee, or panel of independent experts, to consider the drug. According to the McKinsey Center for Government, between 2001 and 2010, the agency approved 88% of products recommended by its advisory committees, so the meeting will be an important hurdle for these companies, especially since they have a great deal riding on one product each. Expect some big movement in stock prices following these meetings.

Do it yourself
First up is Exact Sciences and its colorectal cancer screening test, Cologuard. Last spring the company released top-line data from a 10,000 patient pivotal trial. Results showed a 92% sensitivity for colorectal cancer, but only 42% for pre-cancerous polyps. This was a bit lower than expected, but clearly superior to existing non-invasive screens.

If approved, the screen should please insurers and government payers. The American Cancer Society estimates over 136,000 new cases of combined colon and rectal cancer, and about 50,000 deaths from the disease in 2014. Earlier detection results in far more effective, and less expensive, treatment. As you can imagine, patient compliance for regular screenings is lousy. Cologuard's self-administered sample kit isn't pleasant, but it's a step in the right direction.

New rule
Next up is Durata Therapeutics and its lead product dalbavancin. The FDA sort of moved the goal posts on the previous owner of this antibiotic, Pfizer when it changed a protocol and required an additional non-inferiority study. The requirement was not specific to dalbavancin, but Pfizer washed its hands of the antibiotic anyway. Sensing a low risk opportunity, Durata acquired the rights, then successfully completed the required trial.

Like the Cologuard test, payers have a lot to like about this novel antibiotic. Its advantage lies in its pharmacokinetic profile. A single infusion of dalbavancin remains at an effective level in the blood stream for about a week. This would allow earlier hospital discharges, free up hospital beds and staff, and save a bundle in the process. Given the accelerating growth of antibiotic resistant infections, I'll bet Pfizer wishes it never let this one go.

Deep breaths
April Fool's Day brings us to perhaps the most hotly anticipated advisory committee meeting of the year. MannKind Corporation will take its third swing at approval for its inhaled insulin device, Afrezza.

Unlike Pfizer's misadventure with Exubera, Mannkind argues Afrezza is more than just convenient. It insists it's a more effective treatment for both type 1 and 2 diabetes, and a pair of late stage studies suggests this might be true. In a trial with type 1 patients, Afrezza patients achieved lower fasting blood glucose levels, and a lower rate of total hypoglycemia. In a trial with type 2 patients, Afrezza was more effective at lowering blood sugar than metformin. 

The FDA's main complaint back in 2011 wasn't safety or efficacy of the insulin itself, but rather the next generation inhaler. There wasn't anything identified as wrong with it; the agency just wants to be absolutely certain that data from the old device is "comparable" to the new one.

There are plenty of important questions regarding Afrezza. I think the biggest concern is long-term safety. The company is in the middle of a 52-week study of patients with asthma or chronic obstructive pulmonary disease. The results aren't included in the NDA, but a year of monitoring 510 patients is an awfully big expense. It seems that MannKind has the same lingering concerns.

Biotech isn't the only sector with hyper-growth stocks -- try these 6 on for size!
Finding high-growth stocks at a reasonable price is difficult -- in fact, many people have said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers